

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



1/1177

574f

APPLICANT(S): Jung B. et al
SERIAL NO.: 10/029,905
CONFIRMATION NO.: 5115
FILING DATE: December 21, 2001
DOCKET NO.: 1/1177
TITLE: Method for identifying compounds
which positively influence inflammatory conditions


IN CONNECTION WITH THE ABOVE CASE, PLEASE
DATE STAMP TO ACKNOWLEDGE RECEIPT OF THE
DOCUMENTS LISTED BELOW, AND RETURN TO
ADDRESSEE.

Transmittal Letter for Information Disclosure Statement
(in triplicate)


Information Disclosure Statement w/cited references



Mailed: April 18, 2003



If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



COPY

PTO/SB/08B (02-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Compl t if Known		
			Applicati n Numb r	10/029,905	
			Filing Dat	December 21, 2001	
			First Named Inv ntor	Jung, B. et al	
			Art Unit	1646	
			Examiner Name	To be assigned	
Sheet	1	of	1	Attorney Docket Number	1/1177

OTHER PRIOR ART–NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MENG, L. et al: "Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity", Proc. Natl. Acad. Sci. USA (1999) 96(18):10403-10408.	
		ELOFSSON, M. et al: "Towards Subunit-Specific Proteasome Inhibitors: Synthesis and Evaluation of Peptide Alpha', Beta'-Epoxyketones" Chemistry and Biology (1995) 6(11):811-822.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.